The participants with mild Alzheimer's disease who received 800 mg of Flurizan twice daily, appeared to stabilize and experience no further decline in cognitive function from months twelve to fifteen, as measured by the ADAS-cog (Alzheimer's Disease Assessment Scale, cognitive subscale) test, according to the data from a Phase 2 follow-on study presented by Myriad Genetics.
According to the company release, based on the positive Phase 2 results, Myriad is enrolling patients with mild Alzheimer's disease in its Phase 3 trial, at 130 sites across the United States. This enrolment is proceeding on schedule. The study is designed to determine Flurizan's ability to alter the course of cognitive decline and functional change in patients with mild Alzheimer's disease, as measured by the ADAS-cog test and the change in ADCS-ADL, respectively.
Adrian Hobden, President of Myriad Pharmaceuticals, Inc. said, "The follow-on data show that patients with mild Alzheimer's disease, treated with 800 mg BID of Flurizan, appear not only to have a slowing in loss of cognition as we saw in the Phase 2 study, but may have stopped declining in cognitive ability altogether. We look forward to completing enrolment in the Phase 3 trial in order to confirm these results in a larger patient population."
Flurizan is the first candidate in a new class of drugs known as selective amyloid beta lowering agents (SALAs). Flurizan lowered levels of Abeta42 in cellular assays and animal models.
Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products.